Universal Technical Institute filed its fiscal Q2 results after the close on May 6, beating EPS estimates by a penny while revenue of $221.4M came in fractionally short of the $221.6M consensus. The company reaffirmed full-year revenue guidance of $905M–$915M. The setup heading into that print was the interesting part: shorts had quietly unwound a significant position over the past month, the stock had already climbed nearly 9% on the week, and options traders were leaning decisively bullish.
The most notable positioning shift has been the short-side retreat. SI as a percentage of free float peaked near 7.4% in late March and has since collapsed to 5.8% — a reduction of roughly 22% of the short position in just six weeks. The drop came in a step-change: shares short were running above 3.5 million into late April, then fell sharply around April 24, landing closer to 2.9 million since. That compression is the primary driver behind the week's 8.7% price gain. Borrowing costs remain negligible at 0.47%, and availability is wide — the lending market imposes no friction on new shorts who want in, meaning the cover was a deliberate unwind, not a forced squeeze.
The options market corroborates that directional tilt. The put/call ratio has dropped to 0.53, more than two standard deviations below its 20-day average of 0.62. That's the most call-heavy options positioning UTI has seen in recent memory, a sharp pivot from mid-April when the PCR was running in the mid-0.60s. Peer also had a strong week — up nearly 14% — suggesting broader sentiment across the trades-education space turned constructive heading into earnings season. gained about 2.75% and added 1.5%, but neither matched the move in UTI or Lincoln.
The Street is constructive but has yet to act on the move higher. Both Barrington Research and Rosenblatt maintained existing Buy/Outperform ratings with a $36 price target as recently as April 17 — a target the stock has now traded through, with shares closing at $38.62 on May 5. That means the consensus target of $36 is now below the market price. Whether analysts lift targets in response to the Q2 results and guidance reaffirmation is the immediate question for the sell-side angle. The bull case centres on enrollment growth driven by skilled-trades demand, new campus openings, and a path to $1.2B in revenue by FY29; the bear case flags margin pressure from expansion costs and reliance on a narrow student demographic. With EV/EBITDA now near 18.8x — up roughly 0.7 points on the week — valuation is not stretched for a growth story of this kind, but it is no longer cheap.
Insider activity in the prior 90 days was uniformly selling. The CEO sold $2.1M in late February, the COO disposed of $616K in early March, and the Chief Legal Officer added another $888K of supply in late March. The aggregate net sell figure across all insiders over that window is roughly $6.2M. None of those transactions look panic-driven — prices ranged from $30 to $37.50 — but the pattern does reflect management monetising gains as the stock ran. There were no purchases to offset that flow.
The last two earnings prints produced opposite reactions: a 4.7% one-day gain in March and a 13.2% one-day decline in February. With guidance reaffirmed and the EPS print a modest beat, the next question is whether analyst target revisions follow the stock higher — and whether the short position, now at a six-week low, finds a floor or continues to unwind.
See the live data behind this article on ORTEX.
Open UTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
